Ticker

Algernon Health (CSE:AGN, OTCQB:AGNPF) announced that it has increased the size of its previously announced non-brokered private placement financing to $858,000 and completed the fourth and final tranche of the offering. The Vancouver-based healthcare company said gross proceeds from the final tranche totaled C$117,501, raised through the sale of 1,678,586 units at C$0.07 per unit.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces an increase to its non-brokered private placement financing (the “Offering”), previously announced on November 6, 2025, to…

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF - Get Free Report) was the target of a large drop in short interest during the month of December. As of December 15th, there was short interest totaling 10,835 shares, a drop of 61.9% from the November 30th total of 28,413 shares. Based on an average trading volume of 7,085 shares,

Algernon Health (CSE:AGN, OTCQB:AGNPF) announced an increase to its previously disclosed non-brokered private placement financing to C$750,000 and the closing of the third tranche of the offering. The third tranche generated gross proceeds of C$352,500 through the issuance of 5,035,714 units at a price of C$0.07 per unit.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces an increase to its non-brokered private placement financing, previously announced on November 6, 2025, to $750,000 and the closing…